Skip to main content
Top
Published in: Clinical Rheumatology 1/2022

01-01-2022 | Vasculitis | Original Article

Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease—a retrospective investigation of 845 patients and its clinical relevance

Authors: Hung-Cheng Tsai, Hsiang-Yun Tung, Chih-Wei Liu, Chin-Fang Su, Yi-Syuan Sun, Wei-Sheng Chen, Ming-Han Chen, Chien-Chih Lai, Hsien-Tzung Liao, Ying-Ying Yang, Yi-Hsiang Huang, Chang-Youh Tsai

Published in: Clinical Rheumatology | Issue 1/2022

Login to get access

Abstract

Objective

Immunoglobulin G4-related disease (IgG4-RD) is a recently recognized heterogeneous, subacute, and usually silent autoimmune disease involving many organs with protean manifestations. However, high IgG4 in serum is not necessarily indicating an IgG4-RD. The aims of this study were to investigate the clinical relevance of high serum IgG4 level in IgG4-RD or non IgG4-RD patients, and to see if IgG4-RD in Taiwan differs from that in other parts of the world.

Methods

Eight hundred forty-five patients with high IgG4 were retrospectively reviewed from January 2002 to May 2020 in Taipei Veteran General Hospital. Two hundred sixty-seven patients fulfilled IgG4-RD criteria and were categorized into pancreato-hepato-biliary disease, retroperitoneal fibrosis and/or aortitis, head/neck-limited disease, classic Mikulicz syndrome with systemic involvement, CNS-limited disease, sclerosing vasculitis, skin-limited disease, and sensorineural hearing disease. These manifestations were correlated to smoking, atopy, hyper-IgE/eosinophilia, aging, malignancies, and hypocomplementemia. Five hundred seventy-eight patients were not fulfilling the criteria but were also analyzed for the prevalence of allergy, malignancy, connective tissue diseases, lung diseases, and infections.

Results

In IgG4-RD patients, 124 (46.4%) smoked. Top 4 clinical subtypes included Mikulicz syndrome with systemic involvement (33.3%), pancreato-hepatobiliary disease (31.4%), head/neck disease (19.4%), and retroperitoneal fibrosis/aortitis (12.7%). Top 4 co-morbid conditions included high serum IgE/eosinophilia (46.2%), hypocomplementemia (34%), malignancies (13.4%), and allergy (13.4%). Pancreato-biliary disease was associated with high IgE/eosinophilia (r2 = 0.380, P = 0.025) and malignancy (r2 = 0.211, P = 0.027), Miculicz syndrome with allergy (r2 = 0.396, P < 0.01) and high IgE/eosinophil (r2 = 0.396, P < 0.01), CNS diseases (r2 = 0.973, P = 0.035) and sclerosing vasculitis (r2 = 1, P < 0.01) with advanced age respectively, with the latter being also related to atopy and high IgE/eosinophilia (r2 = 1, p < 0.01).

Conclusion

Smoking may precipitate IgG4-RD. IgG4-RD with pancreato-hepatobiliary disease is closely related to allergy and neoplasm, and those with Mikulicz syndrome may result from atopy. Elderly IgG4-RD patients tend to develop CNS pathology parallel to advancing of age. The disease may probably be originated from an unknown mechanism that may sporadically evolve into malignancies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Umehara H, Okazaki K, Masaki Y et al (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22:1–14CrossRef Umehara H, Okazaki K, Masaki Y et al (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22:1–14CrossRef
2.
go back to reference Stone J, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551CrossRef Stone J, Zen Y, Deshpande V (2012) IgG4-related disease. N Engl J Med 366:539–551CrossRef
3.
go back to reference Ozawa M, Fujinaga Y, Asano J et al (2017) Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study. Arthritis Res Ther 19:223CrossRef Ozawa M, Fujinaga Y, Asano J et al (2017) Clinical features of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related disease: a case-control study. Arthritis Res Ther 19:223CrossRef
4.
go back to reference Seo N, Kim JH, Byun JH, Lee SS, Kim HJ, Lee MG (2015) Immunoglobulin G4-related kidney disease: a comprehensive pictorial review of the imaging spectrum, mimickers, and clinicopathological characteristics. Korean J Radiol 16:1056–1067CrossRef Seo N, Kim JH, Byun JH, Lee SS, Kim HJ, Lee MG (2015) Immunoglobulin G4-related kidney disease: a comprehensive pictorial review of the imaging spectrum, mimickers, and clinicopathological characteristics. Korean J Radiol 16:1056–1067CrossRef
6.
go back to reference Tsai HC, Liao HT, Tsai CY (2019) Retroperitoneal fibrosis with a damaged kidney in IgG4-related disease. J Clin Rheumatol 10:1097 Tsai HC, Liao HT, Tsai CY (2019) Retroperitoneal fibrosis with a damaged kidney in IgG4-related disease. J Clin Rheumatol 10:1097
7.
go back to reference Umehara H, Okazakib K, Nakamura T et al (2017) Current approach to the diagnosis of IgG4-related disease - combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 27:381–391CrossRef Umehara H, Okazakib K, Nakamura T et al (2017) Current approach to the diagnosis of IgG4-related disease - combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 27:381–391CrossRef
8.
go back to reference Liu Y, Zeng Q, Zhu L, Gao J, Wang Z, Wang Z et al (2020) Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. Rheumatology 8:1–9 Liu Y, Zeng Q, Zhu L, Gao J, Wang Z, Wang Z et al (2020) Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. Rheumatology 8:1–9
11.
go back to reference Zhang W, Stone JH (2019) Management of IgG4-related disease. Lancet Rheumatol 1:e55–e65CrossRef Zhang W, Stone JH (2019) Management of IgG4-related disease. Lancet Rheumatol 1:e55–e65CrossRef
12.
go back to reference Deshpande V, Zen Y, Chan JK et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181–1192CrossRef Deshpande V, Zen Y, Chan JK et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25:1181–1192CrossRef
13.
go back to reference Simpson RS, Lau SKC, Lee JK (2020) Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis 79:549–550CrossRef Simpson RS, Lau SKC, Lee JK (2020) Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis 79:549–550CrossRef
14.
go back to reference Khosroshahi A, Bloch DB, Deshpande V et al (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755–1762CrossRef Khosroshahi A, Bloch DB, Deshpande V et al (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755–1762CrossRef
15.
go back to reference Umehara H, Okazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22:21–30CrossRef Umehara H, Okazaki K, Masaki Y et al (2012) Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22:21–30CrossRef
16.
go back to reference Wallace ZS, Naden RP, Chari S et al (2020) The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 72:7–19CrossRef Wallace ZS, Naden RP, Chari S et al (2020) The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 72:7–19CrossRef
19.
go back to reference Fernandez-Codina A, Martinez-Valle F, Pinilla B et al (2015) IgG4-related disease: results from a multicenter Spanish registry. Medicine (Baltimore) 94:e1275CrossRef Fernandez-Codina A, Martinez-Valle F, Pinilla B et al (2015) IgG4-related disease: results from a multicenter Spanish registry. Medicine (Baltimore) 94:e1275CrossRef
20.
go back to reference Inoue D, Yoshida K, Yoneda N et al (2015) IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 94:e680CrossRef Inoue D, Yoshida K, Yoneda N et al (2015) IgG4-related disease: dataset of 235 consecutive patients. Medicine (Baltimore) 94:e680CrossRef
21.
go back to reference Kamekura R, Takahashi H, Ichimiya S (2019) New insights into IgG4-related disease: emerging new CD4+ T-cell subsets. Curr Opin Rheumatol 31:9–15CrossRef Kamekura R, Takahashi H, Ichimiya S (2019) New insights into IgG4-related disease: emerging new CD4+ T-cell subsets. Curr Opin Rheumatol 31:9–15CrossRef
22.
go back to reference Mattoo H, Mahajan VS, Maehara T et al (2016) Clonal expansion of CD4 (+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol Pract 138:825–838CrossRef Mattoo H, Mahajan VS, Maehara T et al (2016) Clonal expansion of CD4 (+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol Pract 138:825–838CrossRef
23.
go back to reference Perugino CA, Mattoo H, Mahajan VS et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69:1722–1732CrossRef Perugino CA, Mattoo H, Mahajan VS et al (2017) Emerging treatment models in rheumatology: IgG4-related disease: insights into human immunology and targeted therapies. Arthritis Rheumatol 69:1722–1732CrossRef
24.
go back to reference Maehara T, Mattoo H, Mahajan VS et al (2018) The expansion in lymphoid organs of IL-4 (+) BATF (+) T follicular helper cells is linked to IgG4 class switching in vivo. Life Sci Alliance 1:e201800050CrossRef Maehara T, Mattoo H, Mahajan VS et al (2018) The expansion in lymphoid organs of IL-4 (+) BATF (+) T follicular helper cells is linked to IgG4 class switching in vivo. Life Sci Alliance 1:e201800050CrossRef
25.
go back to reference Hershey GK, Friedrich MF, Esswein LA et al (1977) The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 337:1720–1725CrossRef Hershey GK, Friedrich MF, Esswein LA et al (1977) The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 337:1720–1725CrossRef
26.
go back to reference Trampert DC, Hubers LM, van de Graaf SFJ et al (2018) On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta Mol Basis Dis 1864:1401–1409CrossRef Trampert DC, Hubers LM, van de Graaf SFJ et al (2018) On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta Mol Basis Dis 1864:1401–1409CrossRef
27.
go back to reference Garcia-Robaina JC, de la Torre-Morin F, Vazquez-Moncholi C, Fierro J et al (1977) The natural history of Apis-specific IgG and IgG4 in beekeepers. Clin Exp Allergy 27:418–423CrossRef Garcia-Robaina JC, de la Torre-Morin F, Vazquez-Moncholi C, Fierro J et al (1977) The natural history of Apis-specific IgG and IgG4 in beekeepers. Clin Exp Allergy 27:418–423CrossRef
28.
go back to reference Varga E-M, Kausar F, Aberer W et al (2013) Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol 131:1419–1421CrossRef Varga E-M, Kausar F, Aberer W et al (2013) Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol 131:1419–1421CrossRef
29.
go back to reference St-Amour I, Paré I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J et al (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab 33:1983–1992CrossRef St-Amour I, Paré I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J et al (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab 33:1983–1992CrossRef
30.
go back to reference Erden A, Bolek EC, Yardimci KG et al (2019) Do ANCA-associated vasculitides and IgG4-related disease really overlap or not? Int J Rheum Dis 22:1926–1932CrossRef Erden A, Bolek EC, Yardimci KG et al (2019) Do ANCA-associated vasculitides and IgG4-related disease really overlap or not? Int J Rheum Dis 22:1926–1932CrossRef
31.
go back to reference Akiyama M, Takeuchi T (2018) IgG4-related disease: beyond glucocorticoids. Drugs Aging 35:275–287CrossRef Akiyama M, Takeuchi T (2018) IgG4-related disease: beyond glucocorticoids. Drugs Aging 35:275–287CrossRef
32.
go back to reference Mavragani CP, Voulgarelis M (2007) Retroperitoneal fibrosis and c-ANCA positivity. Clin Rheumatol 26:115–116CrossRef Mavragani CP, Voulgarelis M (2007) Retroperitoneal fibrosis and c-ANCA positivity. Clin Rheumatol 26:115–116CrossRef
33.
go back to reference Kaipiainen-Seppänen O, Jantunen E, Kuusisto J et al (1996) Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies. J Rheumatol 23:779–781PubMed Kaipiainen-Seppänen O, Jantunen E, Kuusisto J et al (1996) Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies. J Rheumatol 23:779–781PubMed
34.
go back to reference Martínez-Odriozola P, Gutiérrez-Macías A, Moina Eguren I et al (2008) Association of idiopathic retroperitoneal fibrosis, rapidly progressive glomerulonephritis and antiproteinase 3 antineutrophil cytoplasmic antibodies (anti PR3-ANCA). Clin Nephrol 70:251–254CrossRef Martínez-Odriozola P, Gutiérrez-Macías A, Moina Eguren I et al (2008) Association of idiopathic retroperitoneal fibrosis, rapidly progressive glomerulonephritis and antiproteinase 3 antineutrophil cytoplasmic antibodies (anti PR3-ANCA). Clin Nephrol 70:251–254CrossRef
36.
go back to reference Yamamoto M, Takahashi H, Tabeya T et al (2012) Risk of malignancies in IgG4-related disease. Mod Rheumatol 22:414–418CrossRef Yamamoto M, Takahashi H, Tabeya T et al (2012) Risk of malignancies in IgG4-related disease. Mod Rheumatol 22:414–418CrossRef
37.
go back to reference Hirano K, Tada M, Sasahira N et al (2014) Incidence of malignancies in patients with IgG4-related disease. Intern Med 53:171–176CrossRef Hirano K, Tada M, Sasahira N et al (2014) Incidence of malignancies in patients with IgG4-related disease. Intern Med 53:171–176CrossRef
38.
go back to reference Asano J, Watanabe T, Oguchi T et al (2015) Association between Immunoglobulin G4-related disease and malignancy within 12 years after diagnosis: an analysis after longterm followup. J Rheumatol 42:2135–2142CrossRef Asano J, Watanabe T, Oguchi T et al (2015) Association between Immunoglobulin G4-related disease and malignancy within 12 years after diagnosis: an analysis after longterm followup. J Rheumatol 42:2135–2142CrossRef
Metadata
Title
Significance of high serum IgG4 in complete or non-full-fledged IgG4-related disease—a retrospective investigation of 845 patients and its clinical relevance
Authors
Hung-Cheng Tsai
Hsiang-Yun Tung
Chih-Wei Liu
Chin-Fang Su
Yi-Syuan Sun
Wei-Sheng Chen
Ming-Han Chen
Chien-Chih Lai
Hsien-Tzung Liao
Ying-Ying Yang
Yi-Hsiang Huang
Chang-Youh Tsai
Publication date
01-01-2022
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 1/2022
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05772-x

Other articles of this Issue 1/2022

Clinical Rheumatology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.